New bone drug compared to standard care for myeloma
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is testing a new drug called narlumosbart (a type of targeted biologic medicine) compared to denosumab (a standard bone-strengthening treatment) for people with multiple myeloma that has caused bone damage. The goal is to see which drug better protects bones and reduces complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been recently diagnosed with active multiple myeloma (meeting IMWG 2014 criteria).
- You must have at least one sign of bone damage from the myeloma (e.g., visible on X-ray, CT, MRI, or PET).
- You cannot have had certain bone medicines like denosumab or bisphosphonates in the past 6 months.
- You must be in generally decent overall health (adequate liver, kidney, and heart function).
- You cannot have active jaw problems or planned dental surgery that could affect healing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
This trial compares two treatments for newly diagnosed multiple myeloma patients who are not eligible for or have delayed stem cell transplant. One group gets elranatamab plus a light version of RVd (lenalidomide, bortezomib, dexamethasone), and the other gets daratumumab plus the same light RVd. The goal is to find which combination works better.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.